Skip Navigation

Research Funding

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

January 2014 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Centers for Medical Countermeasures Against Radiation

For the published request for applications, see the June 16, 2014, Guide announcement, Centers for Medical Countermeasures Against Radiation Consortium (U19).

Development of Medical Countermeasures to Mitigate or Treat Radiation-Induced Lung Injury After a Nuclear Radiation Incident

For the published broad agency announcement, see the April 29, 2014, solicitation, Development of Medical Countermeasures to Mitigate and/or Treat Radiation-Induced Lung Injury After a Radiological/Nuclear Incident.

Radiation and Nuclear Medical Countermeasure Product Development Support Services

Request for Proposals

Contact: Deborah Blyveis

Objective: To provide additional funds to continue and expand nonclinical and clinical efforts for product development of radiation and nuclear medical countermeasure candidate drugs and biodosimetry devices for inclusion in the Strategic National Stockpile for use during a radiation emergency.

Description: The initiative will provide funds to continue and expand the development of radiation countermeasures for the Radiation and Nuclear Countermeasures Program. The program will provide a comprehensive and broad range of nonclinical and clinical support services that will be available to organizations (companies, government, academic, and Centers for Medical Countermeasures Against Radiation) that have promising medical countermeasure candidates. The program will support product development efforts for licensure of both candidate drugs and biodosimetry devices. The types of product development support services include screening and efficacy evaluation of candidate drugs, Good Laboratory Practice (GLP) toxicology and safety pharmacology in animal models, current Good Manufacturing Practice (cGMP) manufacturing support, GLP pivotal animal efficacy studies, phase I clinical safety and pharmacokinetic studies, and regulatory submission support for candidate drugs and biodosimetry devices.​​

Last Updated June 17, 2014

Last Reviewed February 13, 2014